Aminooxyacetic Acid (Synonyms: Aminooxyacetate) |
Catalog No.GC45380
One-Click Copy Product Info
|
Aminooxyacetic acid is a gamma-aminobutyric acid transaminase (GABA-T) inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 645-88-5
Sample solution is provided at 25 µL, 10mM.
Aminooxyacetic acid is a gamma-aminobutyric acid transaminase (GABA-T) inhibitor. Aminooxyacetic acid exerts anticonvulsant effects by reducing GABA degradation and increasing brain GABA levels. Aminooxyacetic acid regulates hydrogen sulfide metabolism by inhibiting cystathionine beta-synthase and cystathionine gamma-lyase. Aminooxyacetic acid can be used for research on neurological diseases such as epilepsy and hydrogen sulfide metabolism[1-4].
In vitro, treatment of C6 glioma cells with 1-5mM Aminooxyacetic acid for 1-24 hours reduced intracellular ATP levels. Aminooxyacetic acid reduced glycolytic rate and extracellular lactate and pyruvate levels. Aminooxyacetic acid increased the proportion of cells in G0/G1 phase arrest. Aminooxyacetic acid reduced the proportion of cells in S phase and G2/M phase. Aminooxyacetic acid increased the proportion of early apoptotic and necrotic cells[5]. Treatment of ethanol-exposed SH-SY5Y cells with 0.5mM Aminooxyacetic acid for 12 hours reduced intracellular calcium concentration. Aminooxyacetic acid restored mitochondrial membrane potential and weakened BIP and Sec61a protein binding[6]. Treatment of MDA-MB-231 NQO1+, MDA-MB-231 NQO1-, MDA-MB-468 and T47D breast cancer cells with 100μM Aminooxyacetic acid for 2 hours reduced intracellular enrichment of alanine, citrate, glutamate and succinate[7].
In vivo, intraperitoneal injection of 10mg/kg Aminooxyacetic acid to C57BL/6J mice for 3 days after myocardial infarction surgery increased left ventricular ejection fraction and fractional shortening. Aminooxyacetic acid reduced infarct size. Aminooxyacetic acid reduced M1 macrophage proportion and increased M2-like phenotype proportion in ischemic myocardium[8]. Intraperitoneal injection of 5mg/kg Aminooxyacetic acid to acute colitis C57BL/6 mouse model for 5 days alleviated body weight loss and reduced disease activity index. Aminooxyacetic acid attenuated colon shortening and splenomegaly. Aminooxyacetic acid reduced mucosal and submucosal inflammatory cell infiltration and maintained colonic mucosal integrity[9]. Subcutaneous injection of 2mg/kg Aminooxyacetic acid every 6 hours for 24 hours (total dose 10mg/kg) to Nu/nu BALB/C mice subcutaneously implanted with HCT116 cells inhibited liver CBS activity[10].
References:
[1] Carmona E, Gomes C, Trolin G. Effect of aminooxyacetic acid (AOAA) on GABA levels in some parts of the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1980 May;312(1):51-5.
[2] Beal MF, Swartz KJ, Hyman BT,et al. Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. J Neurochem. 1991 Sep;57(3):1068-73.
[3] Kovaleva LV, Zakharova EV, Timofeeva GV, et al. Aminooxyacetic acid (AOA), inhibitor of 1-aminocyclopropane-1-carboxilic acid (ACC) synthesis, suppresses self-incompatibility-induced programmed cell death in self-incompatible Petunia hybrida L. pollen tubes. Protoplasma. 2020;257(1):213-227.
[4] Som R, Fink BD, Yu L, et al. Effect of the mitochondrial transaminase (GOT2) on membrane potential-sensitive respiration in mitochondria of differentiated C2C12 muscle cells. Am J Physiol Cell Physiol. 2024;326(6):C1669-C1682.
[5] Wang C, Chen H, Zhang M, et al. Malate-aspartate shuttle inhibitor aminooxyacetic acid leads to decreased intracellular ATP levels and altered cell cycle of C6 glioma cells by inhibiting glycolysis. Cancer Lett. 2016;378(1):1-7
[6] Sun Z, Nie M, Wang X, et al. Aminooxyacetic acid ameliorates alcohol-induced learning and memory deficits through BDNF-TrkB pathway and calcium homeostasis. Eur J Med Res. 2025;30:365.
[7] Chang MC, Mahar R, McLeod MA, et al. Synergistic Effect of β-Lapachone and Aminooxyacetic Acid on Central Metabolism in Breast Cancer. Nutrients. 2022 Jul;14(15):3020.
[8] Zhao P, Zhou W, Zhang Y, et al. Aminooxyacetic acid attenuates post-infarct cardiac dysfunction by balancing macrophage polarization through modulating macrophage metabolism in mice. J Cell Mol Med. 2020;24(5):2593-2609.
[9] Li W, Yu J, Jin B, et al. Protective Effects of Aminooxyacetic Acid on Colitis Induced in Mice with Dextran Sulfate Sodium. Biomed Res Int. 2021;2021:1477345.
[10] Hellmich MR, Chao C, Modis K, et al. Efficacy of Novel Aminooxyacetic Acid Prodrugs in Colon Cancer Models: Towards Clinical Translation of the Cystathionineβ-Synthase Inhibition Concept. Biomolecules. 2021;11(8):1073.
| Cell experiment [1]: | |
|
Cell lines |
C6 glioma cells (rat glioma cell line) |
|
Preparation Method |
C6 glioma cells were maintained in DMEM containing 4500mg/L D-glucose, 584mg/L L-glutamine and 10% FBS at 37°C, 5% CO2. C6 glioma cells were treated with Aminooxyacetic acid at 1-5mM for 1h, 3h, 5h or 24h. After treatment, intracellular LDH assay, Annexin V/7-AAD flow cytometry, cell cycle analysis, ATP bioluminescence assay, JC-1 assay, 2-NBDG uptake assay, extracellular lactate and pyruvate spectrophotometric assay were performed. |
|
Reaction Conditions |
1-5mM; 1-24h |
|
Applications |
Aminooxyacetic acid decreased intracellular ATP levels at 3h and 5h. Aminooxyacetic acid increased G0/G1 phase arrest and decreased S and G2/M phase proportions. Aminooxyacetic acid increased early-stage apoptosis and necrosis proportions. Aminooxyacetic acid decreased glycolytic rate, extracellular lactate, extracellular pyruvate and (pyruvate+lactate) levels at 1h. Aminooxyacetic acid did not affect mitochondrial membrane potential. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6J mice aged 8-10 weeks with myocardial infarction (permanent LAD ligation) |
|
Preparation Method |
Mice were intraperitoneally administered 10mg/kg Aminooxyacetic acid (dissolved in saline, 1mg/mL) or saline alone once daily for 3 consecutive days starting after MI surgery. Mice were sacrificed at day 3 or day 28 for echocardiography, Masson's trichrome staining, H&E staining, immunofluorescence, Western blot and qPCR. |
|
Dosage form |
10mg/kg; i.p.; 3 days |
|
Applications |
Aminooxyacetic acid increased left ventricle ejection fraction and fractional shortening at day 28. Aminooxyacetic acid reduced Masson's trichrome fibrosis area. Aminooxyacetic acid reduced F4/80+iNOS+ M1-like macrophage proportion and increased F4/80+Arg1+ M2-like macrophage proportion in infarct border zone at day 3. Aminooxyacetic acid reduced iNOS and Arg1 protein and mRNA levels in heart tissue. Aminooxyacetic acid reduced H&E inflammatory cell infiltration and TNF-α positive cells, and increased CD206 positive cells at day 3. Aminooxyacetic acid reduced IL-6 and TNF-α mRNA and increased IL-10 mRNA in heart tissue. Aminooxyacetic acid reduced NLRP3 and Caspase1 protein and IL-1β mRNA in heart tissue at day 3. |
References: [1] Wang C, Chen H, Zhang M, et al. Malate-aspartate shuttle inhibitor aminooxyacetic acid leads to decreased intracellular ATP levels and altered cell cycle of C6 glioma cells by inhibiting glycolysis. Cancer Lett. 2016;378(1):1-7. [2] Zhao P, Zhou W, Zhang Y, et al. Aminooxyacetic acid attenuates post-infarct cardiac dysfunction by balancing macrophage polarization through modulating macrophage metabolism in mice. J Cell Mol Med. 2020;24(5):2593-2609. | |
| Cas No. | 645-88-5 | SDF | |
| Synonyms | Aminooxyacetate | ||
| Chemical Name | 2-(aminooxy)-acetic acid | ||
| Canonical SMILES | OC(CON)=O | ||
| Formula | C2H5NO3 | M.Wt | 91.1 |
| Solubility | 5mg/mL in DMSO, 2mg/mL in DMF | Storage | Store at -20°C, protect from light |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 10.9769 mL | 54.8847 mL | 109.7695 mL |
| 5 mM | 2.1954 mL | 10.9769 mL | 21.9539 mL |
| 10 mM | 1.0977 mL | 5.4885 mL | 10.9769 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)